“These results are exciting because depression is common in Parkinson’s but we weren’t sure about the best way to treat it. Older antidepressants are effective but have a lot of side effects.
The newer antidepressants have fewer side effects but we didn’t know if they’d be effective in people with Parkinson’s. We were also worried that they might worsen the motor problems that come with the disease,” said research author Irene H. Richard, MD, of the University of Rochester Medical Center in New York and a member of the American Academy of Neurology.
Parkinson's disease is a chronic neurologic disorder that worsens over time, leaving patients less able to direct or control their movements due to the loss of cells in various parts of the brain. In addition to the physical problems, Parkinson’s can also cause psychological symptoms. Almost one-half of people with Parkinson’s suffer from depression, and it is a major cause of disability.
The drugs tested were paroxetine, which is an antidepressant in the class called selective serotonin reuptake inhibitors (SSRIs), and venlafaxine extended release, which is in the serotonin and norepinephrine reuptake inhibitors (SNRIs) class.
The clinical trial lasted three months and involved 115 people in various stages of Parkinson’s disease who met the criteria for depression. About one-third of the participants received paroxetine, one-third received venlafaxine and one-third received a dummy pill. The dosage of the drug could be increased until the participant’s depression was effectively treated.On average, the people receiving paroxetine had a 13 point (59 percent) improvement and those receiving venlafaxine had an 11 point (52 percent) improvement in their scores on the Hamilton Rating Scale for Depression. People who received the dummy pill had a 6.8 point (32 percent) improvement. The results, as measured by three other depression rating scales, were similar. “The study suggests that, while there is a clear ‘placebo’ effect, there is a greater benefit from the antidepressant medications,” said Richard.
The study was supported by the National Institutes of Health/National Institute of Neurological Disorders and Stroke and Johns Hopkins University School of Medicine. Wyeth Pharmaceuticals provided venlafaxine XR, while Glaxo-Smith Kline provided paroxetine.
The American Academy of Neurology, an association of 25,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as stroke, Alzheimer’s disease, epilepsy, Parkinson’s disease and multiple sclerosis.
For more information about the American Academy of Neurology, visit http://www.aan.com
Rachel L. Seroka | American Academy of Neurology
Study relating to materials testing Detecting damages in non-magnetic steel through magnetism
23.07.2018 | Technische Universität Kaiserslautern
Innovative genetic tests for children with developmental disorders and epilepsy
11.07.2018 | Christian-Albrechts-Universität zu Kiel
New design tool automatically creates nanostructure 3D-print templates for user-given colors
Scientists present work at prestigious SIGGRAPH conference
Most of the objects we see are colored by pigments, but using pigments has disadvantages: such colors can fade, industrial pigments are often toxic, and...
Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...
Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.
When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...
Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.
Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....
Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.
Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...
17.08.2018 | Event News
08.08.2018 | Event News
27.07.2018 | Event News
17.08.2018 | Physics and Astronomy
17.08.2018 | Information Technology
17.08.2018 | Life Sciences